Central Serous Chorioretinopathy: Etiology, Course and Prognosis

checkorphan
Learn more about:
Central serous chorioretinopathy
Related Clinical Trial
Eplerenone Versus PDT: Comparative Study by OCTA Pilot Study on Deep Learning in the Eye Panmacular Versus Minimal Micropulse Laser Therapy in Central Serous Chorioretinopathy OCT in Rare Chorioretinal Diseases Evaluation of the Precision of the Microperimetry Function of the Spectral OCT/SLO Selective RPE Laser Treatment (SRT) for Various Macular Diseases Selective Retinal Pigment Epithelium Laser Therapy for Macular Disease of the Retina Non-damaging Retinal Laser Therapy With PASCAL Laser for Macular Diseases Intravitreal Bevacizumab for the Treatment of Central Serous Chorioretinopathy Photodynamic Therapy Using Verteporfin for Treatment of Chronic Central Serous Chorioretinopathy (CSC) Eye Patch Therapy for Central Serous Retinopathy (CSR) Multimodal Imaging in Central Serous Chorioretinopathy PRedictive Factors and Changes From Treatment in iPCV Versus CSR Versus nAMD With afLibercept Microperimetric Evaluation After Half-dose Photodynamic Therapy for Chronic Central Serous Chorioretinopathy Eplerenone For the Treatment of Chronic Central Serous Chorioretinopathy Pseudo-PDT in Central Serous Chorioretinopathy Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD Bevacizumab Versus Micropulse in Central Serous Chorioretinopathy (CSC) Study of Photodynamic Therapy (PDT) in Patients With Central Serous Chorioretinopathy (CSC) Selective Retina Therapy With Real-Time Feedback-Controlled Dosimetry for Treating Acute Idiopathic Central Serous Chorioretinopathy in Korean Patients Selective Retina Therapy (SRT) in Patients With Idiopathic Central Serous Retinopathy Effects of OCTA-guided PDT in Acute CSC Efficacy and Safety of Intravitreal Aflibercept Injection for Subacute Central Serous Chorioretinopathy Photodynamic Therapy Versus Eplerenone: Treatment Trial for Chronic Central Serous Chorioretinopathy Micropulse 577nm Laser vs Traditional Laser Treatment in Central Serous Chorioretinopathy The Changes of Retinal Capillaries After Half-dose PDT Measured by OCTA in Eyes With CSC Ranibizumab Versus Low-fluence Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinopathy Treatment Trial for Acute Central Serous Chorioretinopathy The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy Eplerenone Treatment for Chronic Central Serous Chorioretinopathy in Hungarian Population A Pilot Study of the Treatment of Central Serous Chorioretinopathy With Ketoconazole Selective Retina Therapy With ‘R:GEN’ in Patients With Central Serous Chorioretinopathy 577nm Micropulse Laser vs Half-dose Photodynamic Therapy on Acute Central Serous Chorioretinopathy Central Serous Chorioretinopathy: Etiology, Course and Prognosis A Study of the Beneficial Effects of Eplerenone on Central Serous Chorioretinopathy Treatment of Chronic Central Serous Chorioretinopathy Via Electromagnetic Stimulation and Platelet- Rich Plasma Brinzolamide for the Treatment of Chronic Central Serous Chorioretinopathy The Effect of Therapy With Bevacizumab in Chronic Central Serous Chorioretinopathy Eplerenone for the Treatment of Central Serous Chorioretinopathy Micropulse Diode Laser Treatment for Chronic Central Serous Chorioretinopathy Comparison of Multifocal Electroretinogram Assessment in Chronic Central Serous Chorioretinopathy (CSC) Between Laser Treatment Group and Photodynamic Therapy Group in Chronic Central Serous Chorioretinopathy Study on the Use of Micropulse Laser to Treat Central Serous Chorioretinopathy Optical Coherence Tomography Angiography (OCT-A) and Central Serous Chorioretinopathy (CSC) Intravitreal Ranibizumab Treatment of Central Serous Chorioretinopathy Effect of Helicobacter Pylori Treatment on Idiopathic Central Serous Chorioretinopathy (ICSCR) Treatment of Chronic Central Serous Chorioretinopathy With Open-Label Anecortave Acetate Short-Term Oral Mifepristone for Central Serous Chorioretinopathy Methotrexate for Central Serous Chorioretinopathy Treatment Trial Central Serous Chorioretinopathy Treated by Modified Photodynamic Therapy Prospective Randomized Controlled Treatment Trial for Chronic Central Serous Chorioretinopathy The Safe Effective Light Dose of Photodynamic Therapy for Chronic Central Serous Chorioretinopathy Eplerenone for Central Serous Chorioretinopathy High-dose Antioxidants for Central Serous Chorioretinopathy

Brief Title

Central Serous Chorioretinopathy: Etiology, Course and Prognosis

Official Title

Central Serous Chorioretinopathy: An Observational Study About Etiology, Course and Prognosis

Brief Summary

      Pathogenesis of central serous chorioretinopathy is not entirely understood yet, therefore
      further investigations are needed. During this study patients with an acute episode of
      central serous chorioretinopathy are observed with established ophthalmologic methods
      (multimodal imagine) every 6 weeks until subretinal fluid is reabsorbed to gain further
      insides in etiology, course and prognosis of this disease.

Detailed Description

      Patients with central serous chorioretinopathy are recruited from the Department of
      Ophthalmology at the Medical University of Vienna. All patients undergo ETDRS visual acuity
      measurement, Pelli-Robson contrast examination, Amsler-Grid testing, questionnaire testing,
      ophthalmologic examination, SD-OCT and polarization-sensitive OCT, fundus autofluorescence,
      fluorescein angiography, indocyanine-green angiography, fundus photo and microperimetry.
      Patients are re-examined after an interval of 6 weeks until subretinal fluid is entirely
      reabsorbed to gain further insides in etiology, course and prognosis of this disease.

Study Type

Observational

Primary Outcome

Clinical Outcome

Secondary Outcome

 Subclinical Data

Condition

Central Serous Chorioretinopathy

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Estimated Enrollment

50

Start Date

April 2011

Completion Date

April 2013

Primary Completion Date

April 2013

Eligibility Criteria

        Inclusion Criteria:

          -  Signed informed consent form

          -  Age over 18 years

          -  acute episode of Central Serous Chorioretinopathy

          -  Symptoms for less than two weeks

          -  no treatment on study eye

        Exclusion Criteria:

          -  bad compliance

          -  protected patient group (pregnant women)

Gender

All

Ages

18 Years - N/A

Accepts Healthy Volunteers

No

Contacts

Stefan Sacu, Ass.Prof.Dr., ,

Location Countries

Austria

Location Countries

Austria

Administrative Informations

NCT ID

NCT01378130

Organization ID

EK 180/2011

Responsible Party

Principal Investigator

Study Sponsor

Medical University of Vienna

Study Sponsor

Stefan Sacu, Ass.Prof.Dr., Principal Investigator, Department of Ophthalmology, Medical University of Vienna, Austria

Verification Date

April 2013